• Mohamed G ElBanan, Ahmed M Amer, Pascal O Zinn, and Rivka R Colen.
• Department of Diagnostic Radiology, MD Anderson Cancer Center, University of Texas, 1400 Pressler Street, Houston, TX 77030, USA.
• Neuroimaging Clin. N. Am.. 2015 Feb 1;25(1):141-53.

AbstractGlioblastoma (GBM) is the most common and most aggressive primary malignant tumor of the central nervous system. Recently, researchers concluded that the "one-size-fits-all" approach for treatment of GBM is no longer valid and research should be directed toward more personalized and patient-tailored treatment protocols. Identification of the molecular and genomic pathways underlying GBM is essential for achieving this personalized and targeted therapeutic approach. Imaging genomics represents a new era as a noninvasive surrogate for genomic and molecular profile identification. This article discusses the basics of imaging genomics of GBM, its role in treatment decision-making, and its future potential in noninvasive genomic identification.Copyright © 2015 Elsevier Inc. All rights reserved.

22 keywords...

hide…